MCID: CTN003
MIFTS: 52

Cutaneous Lupus Erythematosus

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

MalaCards integrated aliases for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 74 52 36 15 17
Lupus Erythematosus, Cutaneous 52 71
Lupus Erythematosus Cutaneous 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169
KEGG 36 H01595
UMLS 71 C0024137

Summaries for Cutaneous Lupus Erythematosus

KEGG : 36 Cutaneous lupus erythematosus (CLE) is the skin-related form of lupus erythematosus (LE), with a broad spectrum of clinical manifestations and a variable course. CLE is a frequent finding in patients with systemic lupus erythematosus (SLE) and can also exist as a single entity without associated systemic autoimmunity (LE-specific skin disease). Despite ongoing research into the cause of CLE, it remains unclear how CLE relates to SLE pathogenesis. LE-specific skin disease includes the subtypes of CLE such as acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), chronic cutaneous LE (CCLE), and intermittent CLE (ICLE). ACLE is characterized by malar rash or maculopapular eruption on sun exposed areas. SCLE characteristically presents as annular or psoriasiform plaques in a photo distribution. CCLE can be further divided into discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain LE (CLE), and LE tumidus (LET). The pathogenesis of CLE is multifactorial and involves genetic predisposition, environmental triggers, and abnormalities in the immune response. It has been reported that many genetic risk factors for CLE involve HLA or interferon-related pathways. Corticosteroids and antimalarials were considered as the most suitable and effective systemic drugs for CLE patients.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to subacute cutaneous lupus erythematosus and drug-induced lupus erythematosus, and has symptoms including pruritus and exanthema. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs belimumab and Immunosuppressive Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

Wikipedia : 74 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Rare Cutaneous Lupus Erythematosus Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 675)
# Related Disease Score Top Affiliating Genes
1 subacute cutaneous lupus erythematosus 35.3 TRIM21 TNF
2 drug-induced lupus erythematosus 31.1 TNF IL6 IL10
3 exanthem 31.1 TRIM21 TNF IL6 IL10 CD40LG
4 lupus erythematosus 31.0 TRIM21 TREX1 TNF RO60 MX1 IRF5
5 thyroiditis 31.0 TNF IL6 IL10
6 stevens-johnson syndrome/toxic epidermal necrolysis 30.8 IFNG CXCR3 CCL17
7 rosacea 30.7 TNF IL6 IL18
8 acute graft versus host disease 30.7 TNF IL18 IL10 IFNG
9 keratoconjunctivitis sicca 30.7 TRIM21 RO60 CD40LG
10 graft-versus-host disease 30.7 TNF IL6 IL10 IFNG
11 herpes zoster 30.6 TNF IL10 IFNG CD40LG
12 antiphospholipid syndrome 30.6 TNF SELE CD40LG
13 urticaria 30.6 TNF SELE IL6 CD40LG
14 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 TNFSF13B IL17A IL10 IFNG
15 localized scleroderma 30.5 TNFSF13B TNF SELE IL6
16 rheumatic disease 30.4 TRIM21 TNF IL18 IL10 IFNG CD40LG
17 myositis 30.3 TRIM21 TNF IL6 IL17A IFNG
18 myasthenia gravis 30.3 TNFSF13B TNF IL10 IFNG
19 purpura 30.3 TNFSF13B TNF IL6 IL10 CD40LG
20 nervous system disease 30.3 TNF IL6 IFNG CXCR3
21 acute pancreatitis 30.3 TNF IL6 IL18 IL10
22 hepatitis b 30.2 TNF MX1 IL6 IFNG
23 cellulitis 30.2 TNF IL6 IL10 CD40LG
24 neuroretinitis 30.2 IFNG CD40LG
25 pericarditis 30.2 TNF IL6 IFNG CD40LG
26 chronic inflammatory demyelinating polyradiculoneuropathy 30.1 IL17A IL10 IFNG
27 xerophthalmia 30.1 TRIM21 TNFSF13B RO60 CD40LG
28 actinic prurigo 30.1 TNF SELE ICAM1
29 juvenile rheumatoid arthritis 30.1 TNF IL6 IL18 IL10 IFNG
30 lymphopenia 30.1 TYK2 IL6 IL18 IL10 IFNG
31 aggressive periodontitis 30.0 TNF IL6 IL17A IL10
32 sialadenitis 30.0 TRIM21 TNFSF13B TNF RO60
33 cryptococcosis 30.0 TNF IL17A IL10 IFNG
34 peripheral nervous system disease 30.0 TNF IL6 IL17A IL10 IFNG CD40LG
35 connective tissue disease 30.0 TNFSF13B TNF IL6 IL17A IL10 IFNG
36 lymphadenitis 29.9 TNF IL18 IL10 IFNG ICAM1 CXCR3
37 influenza 29.8 TNF MX1 IRF7 IL6 IFNG
38 migraine with or without aura 1 29.8 TREX1 TNF IL6 CD40LG
39 spondylitis 29.8 TNF IL6 IL17A IL10 IFNG
40 spondyloarthropathy 1 29.8 TNF IL17A CD40LG
41 erythema multiforme 29.8 TNF IL6 IFNG ICAM1 CXCR3 CCL17
42 hepatitis c 29.8 TYK2 TNF MX1 IRF7 IL10 IFNG
43 vasculitis 29.7 TNFSF13B TNF SELE IL6 IL17A ICAM1
44 aspergillosis 29.6 TNF IL6 IL18 IL10 IFNG CCL17
45 mixed connective tissue disease 29.6 TNFSF13B TNF IL6 IL10 IFNG CD40LG
46 basal cell carcinoma 29.6 TNF KRT15 IL6 IL10 ICAM1
47 leishmaniasis 29.6 TNF IL6 IL18 IL17A IL10 IFNG
48 sarcoidosis 1 29.6 TNF IL18 IFNG ICAM1 CXCR3 CD40LG
49 common variable immunodeficiency 29.6 TNFSF13B TNF IL6 IL10 IFNG CD40LG
50 bronchiolitis obliterans 29.6 TNF IL6 IL17A IL10 IFNG CXCR3

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


pruritus, exanthema

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CD40LG ICAM1 IL10 IL17A IL18 MX1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CD40LG ICAM1 IL10 IL17A IL18 MX1

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 CCL17 CD40LG CXCR3 ICAM1 IFNG IL10
2 immune system MP:0005387 10.32 CCL17 CD40LG CXCR3 ICAM1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.31 CD40LG CXCR3 ICAM1 IFNG IL10 IL17A
4 cellular MP:0005384 10.26 CCL17 CD40LG CXCR3 ICAM1 IFNG IL10
5 cardiovascular system MP:0005385 10.19 CD40LG CXCR3 ICAM1 IFNG IL10 IL18
6 mortality/aging MP:0010768 10.13 CD40LG CXCR3 ICAM1 IFNG IL10 IL17A
7 digestive/alimentary MP:0005381 10.11 ICAM1 IFNG IL10 IL17A IL18 IL6
8 integument MP:0010771 10.1 CD40LG ICAM1 IFNG IL10 IL17A IL18
9 renal/urinary system MP:0005367 9.76 CD40LG CXCR3 IFNG IL17A IL6 RO60
10 respiratory system MP:0005388 9.56 CXCR3 IFNG IL10 IL17A IL6 SELE
11 vision/eye MP:0005391 9.28 ICAM1 IFNG IL10 IL18 IL6 IRF7

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
belimumab Approved Phase 4 356547-88-1 5957 10451420
2 Immunosuppressive Agents Phase 4
3 Immunologic Factors Phase 4
4
Hydroxychloroquine Approved Phase 3 118-42-3 3652
5 Anti-Infective Agents Phase 3
6 Antiparasitic Agents Phase 3
7 Antiprotozoal Agents Phase 3
8 Antimalarials Phase 3
9 Protective Agents Phase 3
10 Radiation-Protective Agents Phase 3
11 Sunscreening Agents Phase 3
12
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
13
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
14
Abatacept Approved Phase 2 332348-12-6 10237
15
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
16
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
17
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
18 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
19
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 637568 5271565
20
Norflurane Approved, Experimental Phase 2 811-97-2
21
Etanercept Approved, Investigational Phase 2 185243-69-0
22
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
23
Tofacitinib Approved, Investigational Phase 1, Phase 2 477600-75-2
24
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795 449171
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
26
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
27
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
29
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
30
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
31
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
32 Hypolipidemic Agents Phase 2
33 Vitamin B Complex Phase 2
34 Vitamin B3 Phase 2
35 Vitamin B9 Phase 2
36 Vasodilator Agents Phase 2
37 Folate Phase 2
38 Lipid Regulating Agents Phase 2
39 Nicotinic Acids Phase 2
40 Antimetabolites Phase 2
41 Methylprednisolone Acetate Phase 2
42 Antirheumatic Agents Phase 2
43 Anti-Inflammatory Agents Phase 2
44 Anti-Inflammatory Agents, Non-Steroidal Phase 2
45 Analgesics, Non-Narcotic Phase 2
46 Analgesics Phase 2
47 Gastrointestinal Agents Phase 2
48 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
49 Phosphodiesterase 4 Inhibitors Phase 1, Phase 2
50 Protein Kinase Inhibitors Phase 1, Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Unknown status NCT02270970 Phase 4
2 Efficacy of 595 nm Pulsed-dye Laser as an Adjunctive Treatment of Discoid Lupus Erythematosus, A Randomized, Patient/Assessor Blinded Placebo Control Trial Unknown status NCT03178188 Phase 2, Phase 3
3 A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
4 Photoprotective Effects of the RV 2457C Sunscreen Milk in Photoinduced Cutaneous Lupus Erythematosus Completed NCT00470912 Phase 3 sunscreen RV 2547C
5 A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE) Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
6 An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus Unknown status NCT03260166 Phase 2 nicotinamide
7 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study) Unknown status NCT02270957 Phase 2
8 A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2 KRP203 - 1.2mg;Placebo to KRP203 - 1.2 mg
9 A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2 CC-11050
10 The Efficacy of Topical Tacrolimus in the Treatment of Cutaneous Lupus Erythematosus - a Multi-Center-Trial Completed NCT00317681 Phase 2 Tacrolimus ointment
11 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Mono-Centre, Open-Label, Prospective Pilot Study Completed NCT01352988 Phase 2 Fumaric acid esters
12 Single Blind, Controlled, Single-Center Study of Laser Treatment in Cutaneous Lupus Erythematosus Completed NCT00523588 Phase 2
13 A Single Arm, Phase II Open Label Trial to Investigate the Efficacy and Safety of Intra-dermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Completed NCT02656082 Phase 2 Etanercept
14 Clinical and Immune-modulating Effects of CC-10004 in Discoid Lupus Erythematosus Completed NCT00708916 Phase 1, Phase 2 CC-10004
15 A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
16 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Active, not recruiting NCT03134222 Phase 2 Filgotinib;Lanraplenib;Filgotinib placebo;Lanraplenib placebo
17 A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations Active, not recruiting NCT02847598 Phase 2 BIIB059;Placebo
18 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study Terminated NCT01407679 Phase 2 Alitretinoin
19 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
20 A Double-blind (Sponsor Unblinded) Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Repeat Dosing of GSK2646264 in Cutaneous Lupus Erythematosus Patients Completed NCT02927457 Phase 1 GSK2646264 1%;Placebo
21 A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus Completed NCT01702740 Phase 1 1 mg/kg CNTO 136;4 mg/kg CNTO 136;10 mg/kg CNTO 136;Placebo
22 A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy Completed NCT02652546 Phase 1 Assess Safety;Effect of drug on viral load;Effect of drug on T-cell count;Effect of drug on inflammatory biomarkers
23 A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Recruiting NCT03817424 Phase 1 VIB7734;Placebo
24 A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE) Terminated NCT01470313 Phase 1 PD-0360324;Placebo
25 A Phase I, Open-Label, Dose Escalation Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Cutaneous Lupus (ALE08) Terminated NCT02428309 Phase 1
26 A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1 AMG 557;AMG 557 Placebo
27 European Society of Cutaneous Lupus Erythematosus Unknown status NCT00420121
28 Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Completed NCT02034344
29 Cross-Sectional Study in Subjects With Active Cutaneous Lupus Erythematosus Completed NCT01923415
30 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Completed NCT01629784
31 Interdisciplinary Study Group of Lupus Erythematosus Completed NCT00420173
32 Investigation of the Efficacy of Different Sunscreens in Patients With Photosensitive Cutaneous Lupus Erythematosus Completed NCT01146444
33 A Pilot Study to Evaluate Using Tape Harvesting to Collect Ribonucleic Acid From the Upper Epidermis of Healthy Volunteers and Subjects With Discoid Lupus, Subjects With Subacute Cutaneous Lupus, and Subjects With Atopic Dermatitis Completed NCT02125695
34 Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus Completed NCT00633945 Lenalidomide
35 Proof-of-Concept Study of IVIg Efficacy in Patients With Cutaneous Lupus Erythematosus Completed NCT01841619 Early Phase 1 IVIg
36 Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus Recruiting NCT01510067
37 Low-dose UVA1 Radiation in Cutaneous Lupus Patients Recruiting NCT01776190
38 Duke Lupus Registry Recruiting NCT00512694
39 A Comparative Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone Recruiting NCT03639857 Topical corticosteroid
40 Molecular Studies on Cutaneous Lupus Recruiting NCT01266915
41 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Terminated NCT01559155
42 Evaluation of the Therapeutic Effect and Local Tolerability of Elidel® Cream 1% (Pimecrolimus) in Chronic Discoid Lupus Erythematosus (dLE) or Subacute Cutaneous Lupus Erythematosus (scLE) Withdrawn NCT00222183 Elidel (pimecrolimus)

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

40
Skin, T Cells, Lung, Heart, Kidney, Breast, B Cells

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 1560)
# Title Authors PMID Year
1
CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. 54 61
18280341 2008
2
Elevated soluble E-selectin in cutaneous lupus erythematosus. 54 61
10599337 1999
3
Relationship between heat shock protein induction and the binding of antibodies to the extractable nuclear antigens on cultured human keratinocytes. 54 61
8345220 1993
4
Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. 54 61
2132545 1990
5
Cutaneous lupus erythematosus and its association with systemic lupus erythematosus: A nationwide population-based cohort study in Korea. 61
31773752 2020
6
A Missense Variant Affecting the C-Terminal Tail of UNC93B1 in Dogs with Exfoliative Cutaneous Lupus Erythematosus (ECLE). 61
32028618 2020
7
Management of cutaneous manifestations of lupus erythematosus: A systematic review. 61
31526594 2020
8
Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events. 61
31965545 2020
9
Association between oral lesions and disease activity in lupus erythematosus. 61
31566809 2020
10
Association of herpes zoster and chronic inflammatory skin disease in United States inpatients. 61
31958523 2020
11
Primary Cutaneous Clonal CD8+ T-Cell Lymphoproliferative Disorder Associated With Immunodeficiency due to RAG1 Mutation. 61
31313695 2020
12
Successful treatment with hydroxychloroquine for systemic lupus erythematosus with cutaneous involvement accompanied by a xanthomatous reaction. 61
31789124 2020
13
Proton Pump Inhibitor-Induced Subacute Cutaneous Lupus Erythematosus. 61
31427196 2020
14
Cutaneous lupus erythematosus induced by drugs - novel insights. 61
31774327 2020
15
Principal Components Analysis as a Tool to Identify Lesional Skin Patterns in Cutaneous Lupus Erythematosus. 61
31940464 2020
16
Three cases of subacute cutaneous lupus erythematosus associated with malignancy: a late paraneoplastic phenomenon. 61
31944366 2020
17
[Resistant and progressive cutaneous lupus erythematosus treated with belimumab: A retrospective monocentric study]. 61
31980188 2020
18
Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus. 61
31957866 2020
19
Intravenous Immunoglobulin in the Management of Lupus Erythematosus Panniculitis. 61
32025447 2020
20
Subacute cutaneous lupus erythematosus leukoderma treated with melanocyte-keratinocyte transplantation procedure. 61
30932304 2019
21
Clinicopathologic comparison of Rowell syndrome, erythema multiforme, and subacute cutaneous lupus erythematosus. 61
31629618 2019
22
Childhood subacute cutaneous lupus erythematosus associated with transaminitis. 61
31850540 2019
23
Cutaneous lupus erythematosus: A review of the literature. 61
31909151 2019
24
PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. 61
31826980 2019
25
Staphylococcus aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by IFN-Mediated Barrier Disruption. 61
31877319 2019
26
Cutaneous Lupus Erythematosus Patients With a Negative Antinuclear Antibody Meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics Criteria for Systemic Lupus Erythematosus. 61
31058462 2019
27
Brief Update on Dermatologic Uses of Methotrexate 61
31801013 2019
28
Influenza vaccine-associated cutaneous lupus erythematosus. 61
31675446 2019
29
Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib. 61
31724158 2019
30
Willingness-to-pay stated preferences in cutaneous lupus erythematosus: a pilot study. 61
31773259 2019
31
Subacute cutaneous lupus erythematosus with a possible paraneoplastic association with melanoma. 61
31780613 2019
32
Adult-onset linear discoid lupus erythematosus on the forehead mimicking en coup de sabre: a case report. 61
31771644 2019
33
Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus associated with lung carcinoma. 61
31611227 2019
34
Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab. 61
31735010 2019
35
Autoimmune disease development before and after cutaneous lupus erythematosus diagnosis. 61
31647114 2019
36
A secondary discoid lupus erythematosus induced by scald of edible oil: An illustration of Koebner phenomenon. 61
31660688 2019
37
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice. 61
31693649 2019
38
Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus. 61
31522626 2019
39
Rowell Syndrome in Nigeria: Systemic Lupus Erythematosus Presenting as Recurrent Erythema Multiforme in a Young Woman. 61
31542069 2019
40
Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. 61
31399711 2019
41
A Case of Papulonodular Mucinosis in a Patient With Systemic Lupus Erythematosus. 61
31567136 2019
42
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders. 61
31476936 2019
43
Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. 61
30244487 2019
44
Capecitabine-induced Subacute Cutaneous Lupus Erythematosus. 61
31777367 2019
45
A comedonal variant of chronic cutaneous lupus erythematosus: Case report and literature review. 61
31517002 2019
46
Delineating the Healthy Human Skin UV Response and Early Induction of Interferon Pathway in Cutaneous Lupus Erythematosus. 61
30974166 2019
47
UV radiation exposure in welders: impact on the skin and eyes. 61
31675405 2019
48
Treatment of exfoliative cutaneous lupus erythematosus in a German shorthaired pointer dog with mycophenolate mofetil. 61
31038261 2019
49
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. 61
29912772 2019
50
Metastatic prostate cancer presenting as subacute cutaneous lupus erythematosus. 61
31407804 2019

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

Pathways related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TYK2 TRIM21 TREX1 TNFSF13B TNF MX1
2
Show member pathways
13.86 TNFSF13B TNF IL6 IL18 IL17A IL10
3
Show member pathways
13.71 TYK2 TNFSF13B TNF IL6 IL18 IL17A
4
Show member pathways
13.59 TYK2 TNFSF13B TNF IL6 IL18 IL17A
5
Show member pathways
13.46 TNFSF13B TNF IL6 IL18 IL17A IL10
6
Show member pathways
13.35 TNFSF13B TNF IL6 IL18 IL17A IL10
7
Show member pathways
13.19 TYK2 TNF MX1 IRF7 IRF5 IL6
8
Show member pathways
13.11 TYK2 TRIM21 TNFSF13B TNF MX1 IRF7
9
Show member pathways
12.89 TNFSF13B TNF IL6 IL17A IL10 IFNG
10
Show member pathways
12.85 TYK2 TNF MX1 IRF7 IL6 IL18
11 12.82 TYK2 TNF IRF7 IL6 IFNG
12
Show member pathways
12.82 TREX1 TNF IRF7 IL6 IL18 IFNG
13
Show member pathways
12.68 TNF IL18 IL10 IFNG CD40LG
14
Show member pathways
12.67 TYK2 TNF IL6 IL18 IL17A IL10
15
Show member pathways
12.66 TNF IL6 IL17A IL10 IFNG CD40LG
16
Show member pathways
12.66 TYK2 TNF IL6 IL18 IL17A IL10
17
Show member pathways
12.59 TYK2 TRIM21 MX1 IRF7 IRF5 IFNG
18 12.57 TYK2 TNFSF13B TNF IRF7 IRF5 IL17A
19
Show member pathways
12.42 TNF IL6 IL18 IL10 CXCR3 CCL17
20
Show member pathways
12.4 TNF IL6 IL17A IFNG CCL17
21
Show member pathways
12.38 TYK2 IL6 IL10 IFNG
22
Show member pathways
12.36 TNF IL6 IFNG ICAM1
23
Show member pathways
12.33 TYK2 TNF IL10 IFNG CD40LG
24 12.3 TYK2 TNF IRF7 IL6 IL18
25 12.3 TNF IL6 IL18 IL10 IFNG
26
Show member pathways
12.26 TNF IL6 IL10 CCL17
27
Show member pathways
12.17 TYK2 TNF MX1 IRF7 IRF5 IL6
28 12.14 TNF SELE IFNG ICAM1
29
Show member pathways
12.14 TYK2 TNF IL6 IL18 IL17A IL10
30 12.1 TNFSF13B TNF IL6 IFNG ICAM1
31 12.08 TNF IL6 IL18 IL10
32 12.06 TNF IL6 IL10 IFNG
33 12.06 TYK2 TNF IL6 IL18 IL17A IL10
34 12.04 TNF SELE IL6 ICAM1
35 12.02 IRF7 IRF5 IL6 IFNG
36 12 TNFSF13B TNF ICAM1 CD40LG
37 11.99 TNF IL6 IL10 IFNG
38 11.98 TNF SELE IL6 ICAM1
39 11.95 TYK2 IL6 IL10 IFNG
40 11.89 TNF IL18 IL17A IL10 IFNG CXCR3
41 11.88 SELE IL6 IFNG ICAM1
42 11.88 TNFSF13B TNF IL6 IL18 IL17A IFNG
43 11.83 TNF IL6 IL10 IFNG
44 11.81 IL6 IL18 IFNG
45 11.79 TNF IL6 IL10
46
Show member pathways
11.79 TNF IFNG CD40LG
47
Show member pathways
11.77 TNFSF13B TNF CD40LG
48
Show member pathways
11.77 TNF SELE IL6 IFNG ICAM1 CD40LG
49 11.72 TNF IL6 IL18 IL17A IL10 IFNG
50 11.7 IL10 CD40LG CCL17

GO Terms for Cutaneous Lupus Erythematosus

Cellular components related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 TNFSF13B TNF IL6 IL18 IL17A IL10
2 extracellular space GO:0005615 9.36 TNFSF13B TNF SELE IL6 IL18 IL17A
3 external side of plasma membrane GO:0009897 9.35 TNF IL17A ICAM1 CXCR3 CD40LG

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 TNF IRF7 IRF5 IL6 IL18 IL17A
2 regulation of gene expression GO:0010468 9.99 TREX1 RO60 IRF7 IL10
3 regulation of immune response GO:0050776 9.98 TNFSF13B IRF7 ICAM1 CD40LG
4 cellular response to lipopolysaccharide GO:0071222 9.96 TNF IL6 IL10 ICAM1
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.88 TRIM21 TNF IL6 IL10
6 cellular response to interleukin-1 GO:0071347 9.87 IL17A ICAM1 CCL17
7 regulation of inflammatory response GO:0050727 9.87 TREX1 TNF SELE
8 response to virus GO:0009615 9.86 TNF MX1 IRF7 IFNG
9 response to glucocorticoid GO:0051384 9.85 TNF IL6 IL10
10 defense response to virus GO:0051607 9.85 TREX1 MX1 IRF7 IRF5 IL6 IFNG
11 positive regulation of T cell proliferation GO:0042102 9.84 TNFSF13B IL6 CD40LG
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 TNF IL6 IL18
13 humoral immune response GO:0006959 9.83 TNF IL6 IFNG
14 interleukin-12-mediated signaling pathway GO:0035722 9.8 TYK2 IL10 IFNG
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 TNF IL6 IL18 ICAM1 CD40LG
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 TNF IFNG ICAM1
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 TNF IL6 IL18 IFNG
18 positive regulation of JAK-STAT cascade GO:0046427 9.76 TNF IL6 IL10
19 cytokine-mediated signaling pathway GO:0019221 9.76 TYK2 TNF IRF5 IL6 IL18 IL17A
20 leukocyte cell-cell adhesion GO:0007159 9.74 SELE ICAM1 CD40LG
21 positive regulation of interleukin-12 production GO:0032735 9.72 IRF5 IFNG CD40LG
22 interferon-gamma-mediated signaling pathway GO:0060333 9.72 TRIM21 IRF7 IRF5 IFNG ICAM1
23 positive regulation of chemokine biosynthetic process GO:0045080 9.69 TNF IFNG
24 negative regulation of amyloid-beta clearance GO:1900222 9.69 TNF IFNG
25 negative regulation of myoblast differentiation GO:0045662 9.69 TNF IL18 CCL17
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL10 IFNG
27 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
28 endothelial cell apoptotic process GO:0072577 9.67 TNF IL10
29 positive regulation of osteoclast differentiation GO:0045672 9.67 TNF IL17A IFNG
30 response to peptidoglycan GO:0032494 9.65 IRF5 IL6
31 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 TNF IL10
32 type I interferon signaling pathway GO:0060337 9.65 TYK2 TREX1 MX1 IRF7 IRF5
33 inflammatory response GO:0006954 9.65 TREX1 TNF SELE IL6 IL18 IL17A
34 regulation of immunoglobulin secretion GO:0051023 9.64 TNF CD40LG
35 immunoglobulin secretion GO:0048305 9.64 TNFSF13B CD40LG
36 type 2 immune response GO:0042092 9.63 IL18 IL10
37 positive regulation of interleukin-23 production GO:0032747 9.63 IL17A IFNG
38 regulation of type I interferon production GO:0032479 9.63 TRIM21 TREX1 IRF7
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
40 receptor biosynthetic process GO:0032800 9.61 TNF IL10
41 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF IL6 IL18
42 interferon-alpha production GO:0032607 9.6 TREX1 IRF7
43 T cell antigen processing and presentation GO:0002457 9.59 TREX1 ICAM1
44 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 TNF IFNG
45 positive regulation of nitrogen compound metabolic process GO:0051173 9.52 TNF IFNG
46 immune response GO:0006955 9.36 TREX1 TNFSF13B TNF IL6 IL18 IL17A

Molecular functions related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 TYK2 TRIM21 TNFSF13B TNF SELE MX1
2 cytokine activity GO:0005125 9.28 TNFSF13B TNF IL6 IL18 IL17A IL10
3 tumor necrosis factor receptor binding GO:0005164 9.13 TNFSF13B TNF CD40LG

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....